As of 2025-12-26, the Relative Valuation of Eiger BioPharmaceuticals Inc (EIGR) is (3,801.37) USD. This relative valuation is based on P/E multiples. With the latest stock price at 8.50 USD, the upside of Eiger BioPharmaceuticals Inc based on Relative Valuation is -44822.0%.
The range of the Relative Valuation is (3,057.89) - (4,103.80) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 14.4x - 19.5x | 18.0x |
| Forward P/E multiples | 14.6x - 21.9x | 18.2x |
| Fair Price | (3,057.89) - (4,103.80) | (3,801.37) |
| Upside | -36075.2% - -48380.0% | -44822.0% |
| Date | P/E |